​ACS Discovery Pillar work was noted in publications and recognitions.

• Brian Rivers, PhD, MPH, principal investigator of the Morehouse School of Medicine’s Diversity in Cancer Research Institutional Development Grant, served as a committee member at the National Academies of Sciences, Engineering, and Medicine “Unequal Treatment Revisited: The Current State of Racial and Ethnic Disparities in Health Care Meeting #1” on February 1, 2023. Dr. Rivers was a panelist at the Cancer Moonshot: White House Roundtable Community Conversation Moving on Equity: OCE Expands Diversity Initiative in May 2022. Pictured is Dr. Brian Rivers, Dr. Ellie Daniels, and trainees at the Dr. Curtis Parker Student Research Symposium Day at Morehouse School of Medicine, Atlanta, GA, held on Feb. 8, 2023.

• The FDA recently approved the drug elacestrant as a targeted therapy for some advanced breast cancers. In 2013, ACS Research Professor Arul Chinnaiyan co-discovered the target, mutant estrogen receptor, and Dr. Donald McDonnell (a two-time ACS grantee) and team helped develop the drug.

• ICYMI: American Cancer Society Announces New Center for Diversity in Cancer Research Training (blackenterprise.com)